Patritumab
- Generic Name
- Patritumab
- Drug Type
- Biotech
- CAS Number
- 1262787-83-6
- Unique Ingredient Identifier
- 86780VJI1Q
- Background
Patritumab has been used in trials studying the treatment of LUNG CANCER, Solid Tumors, Neoplasms by Site, Head and Neck Neoplasms, and Non-small Cell Lung Cancer, among others.
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer
- Conditions
- Metastatic Breast CancerAdvanced Breast Cancer
- Interventions
- First Posted Date
- 2021-07-16
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 99
- Registration Number
- NCT04965766
- Locations
- 🇫🇷
Centre Georges François Leclerc, Dijon, France
🇫🇷CHU de Limoges, Limoges, France
🇫🇷Institut Paoli Calmettes, Marseille, France
A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer
- Conditions
- Metastatic Breast CancerLocally Advanced Breast Cancer
- Interventions
- First Posted Date
- 2021-01-07
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 121
- Registration Number
- NCT04699630
- Locations
- 🇺🇸
SCRI Oncology Partners, Nashville, Tennessee, United States
🇺🇸Tennessee Oncology, Nashville, Tennessee, United States
🇺🇸Seattle Cancer Care Alliance, Seattle, Washington, United States
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
- Conditions
- Non-Small Cell Lung Cancer MetastaticNon-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
- Interventions
- First Posted Date
- 2020-11-06
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 277
- Registration Number
- NCT04619004
- Locations
- 🇰🇷
The Catholic University of Korea, Seoul St. Marys Hospital, Seoul, Korea, Republic of
🇳🇱Netherlands Cancer Institute, Amsterdam, Netherlands
🇮🇹Azienda Ospedaliero Universitaria di Parma, Parma, Province Of Parma, Italy
A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer
- First Posted Date
- 2020-07-21
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 40
- Registration Number
- NCT04479436
- Locations
- 🇬🇧
Sarah Cannon Research Institute UK, London, United Kingdom
🇯🇵Kindai University Hospital, Osaka, Osakasayama Shi, Japan
🇪🇸Hospital del Mar - Institut Hospital del Mar d'Investigacions Mediques IMIM, Barcelona, Spain
Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer
- First Posted Date
- 2016-12-02
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 182
- Registration Number
- NCT02980341
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Southeastern Regional Medical Center, Newnan, Georgia, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )
- Conditions
- Head and Neck Neoplasms
- Interventions
- First Posted Date
- 2015-12-17
- Last Posted Date
- 2019-01-07
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 87
- Registration Number
- NCT02633800
- Locations
- 🇫🇷
Hopital Croix-Rousse, Lyon, France
🇵🇱Centrum Onkologii im. Prof. Franciszka Lukaszczyka w Bydgoszczy, Bydgoszcz, Poland
🇧🇪Institut Jules Bordet, Brussels, Belgium
Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- First Posted Date
- 2015-01-30
- Last Posted Date
- 2018-09-11
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 15
- Registration Number
- NCT02350712
- Locations
- 🇬🇧
University College London Hospital, London, United Kingdom
🇬🇧The Royal Marsden Hospital, London, United Kingdom
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
- Conditions
- Lung CancerNon-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2014-05-08
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 145
- Registration Number
- NCT02134015
Study to Assess Pharmacokinetics, Immunogenicity and Safety/Tolerability of Patritumab (U3-1287)
- First Posted Date
- 2013-10-08
- Last Posted Date
- 2014-05-14
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 17
- Registration Number
- NCT01957280
Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC)
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2012-01-19
- Last Posted Date
- 2017-10-18
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 29
- Registration Number
- NCT01512199
- Locations
- 🇦🇷
Instituto Damic - Fundacion Rusculleda, Cordoba, Argentina
🇦🇷Unidad de Investigación FP Clinical Pharma en Centro Medico Integral Fitz Roy, Acevedo, Ciudad Autónoma de Buenos Aires, Argentina
🇦🇷Hospital Britanico, Buenos Aires, Argentina
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.